X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (17) 17
humans (17) 17
index medicus (15) 15
male (15) 15
animals (11) 11
adult (9) 9
human necessities (8) 8
hygiene (8) 8
medical or veterinary science (8) 8
micrococcus - immunology (8) 8
middle aged (8) 8
preparations for medical, dental, or toilet purposes (8) 8
specific therapeutic activity of chemical compounds ormedicinal preparations (8) 8
genotype (7) 7
mice (7) 7
treatment outcome (7) 7
young adult (7) 7
adolescent (6) 6
infectious diseases (5) 5
pharmacokinetics (5) 5
pharmacology & pharmacy (5) 5
protease inhibitors (5) 5
simeprevir (5) 5
viral load (5) 5
antibody formation (4) 4
antiviral agents - administration & dosage (4) 4
antiviral agents - adverse effects (4) 4
antiviral agents - pharmacokinetics (4) 4
antiviral agents - therapeutic use (4) 4
carcinoma, ehrlich tumor - immunology (4) 4
double-blind method (4) 4
healthy volunteers (4) 4
infection (4) 4
protease inhibitor (4) 4
respiratory syncytial virus (4) 4
ribavirin - therapeutic use (4) 4
ritonavir (4) 4
safety (4) 4
sulfonamides - therapeutic use (4) 4
abridged index medicus (3) 3
aged (3) 3
analysis (3) 3
antiviral agents (3) 3
antiviral agents - pharmacology (3) 3
carcinoma, ehrlich tumor - prevention & control (3) 3
care and treatment (3) 3
drug therapy, combination (3) 3
drug-related side effects and adverse reactions - epidemiology (3) 3
drug-related side effects and adverse reactions - pathology (3) 3
efficacy (3) 3
gastroenterology & hepatology (3) 3
genetics & heredity (3) 3
hepacivirus - genetics (3) 3
hepatitis c (3) 3
hepatitis c - drug therapy (3) 3
hepatitis c virus (3) 3
immunology (3) 3
infections (3) 3
mice, inbred balb c (3) 3
mice, inbred strains (3) 3
mutation (3) 3
placebos - administration & dosage (3) 3
ribavirin (3) 3
ritonavir - therapeutic use (3) 3
rna, viral - blood (3) 3
sulfonamides - adverse effects (3) 3
telaprevir (3) 3
time factors (3) 3
virology (3) 3
abnormalities, multiple - genetics (2) 2
administration, oral (2) 2
aids/hiv (2) 2
anti-hiv agents - pharmacokinetics (2) 2
antibodies, bacterial - biosynthesis (2) 2
antiretroviral drugs (2) 2
antiviral activity (2) 2
bacterial vaccines (2) 2
biological response modifiers (2) 2
carbamates - therapeutic use (2) 2
cell division (2) 2
cercopithecus aethiops (2) 2
child (2) 2
concanavalin a - pharmacology (2) 2
convulsions (2) 2
disease (2) 2
disease models, animal (2) 2
dna mutational analysis (2) 2
drug resistance, viral (2) 2
drug therapy (2) 2
drug therapy, combination - adverse effects (2) 2
drug therapy, combination - methods (2) 2
electrophoresis, cellulose acetate (2) 2
epilepsy (2) 2
epileptogenesis (2) 2
gastroenterology and hepatology (2) 2
genetic aspects (2) 2
genotype 1 (2) 2
health aspects (2) 2
hepacivirus - drug effects (2) 2
hepatitis c - virology (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Human Mutation, ISSN 1059-7794, 11/2015, Volume 36, Issue 11, pp. 1080 - 1087
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2015, Volume 10, Issue 5, p. e0126959
Journal Article
Journal Article
Journal of Infectious Diseases, ISSN 0022-1899, 2018, Volume 218, Issue 5, pp. 748 - 756
Journal Article
Gastroenterology, ISSN 0016-5085, 2012, Volume 143, Issue 5, pp. 1176 - 1178.e6
Journal Article
Antiviral Research, ISSN 0166-3542, 05/2018, Volume 153, pp. 70 - 77
Journal Article
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 03/2014, Volume 65, Issue 3, p. 299
  To evaluate safety, tolerability, and pharmacokinetics of TMC310911, a novel human immunodeficiency virus type-1 protease inhibitor. Healthy participants... 
Antiretroviral drugs | Protease inhibitors | Human immunodeficiency virus--HIV | Medical treatment
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 03/2014, Volume 65, Issue 3, pp. 299 - 299
To evaluate safety, tolerability, and pharmacokinetics of TMC310911, a novel human immunodeficiency virus type-1 protease inhibitor. Healthy participants aged... 
Journal Article
Antiviral Therapy, ISSN 1359-6535, 2011, Volume 16, Issue 7, pp. 1021 - 1033
Background: Antiviral activity of TMC435, an oral, once-daily, HCV NS3/4A protease inhibitor, was evaluated with pegylated interferon-alpha 2a/ribavirin (P/R)... 
PROTEASE INHIBITOR | INFECTIOUS DISEASES | VIRUS-INFECTION | TELAPREVIR | PROFILE | VIROLOGY | BOCEPREVIR | PHARMACOLOGY & PHARMACY | RIBAVIRIN | CHRONIC HCV INFECTION | PEGINTERFERON
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 03/2014, Volume 65, Issue 3, pp. 283 - 283
TMC310911 is a novel HIV type-1 (HIV-1) protease inhibitor with broad in vitro antiviral activity. In this phase 2a, open-label randomized study, the antiviral... 
Journal Article
Journal Article
Gastroenterology, ISSN 0016-5085, 2010, Volume 138, Issue 3, pp. 913 - 921
Background & Aims The search for targeted anti-hepatitis C virus (HCV) drugs is driven by the adverse effect profile and limited efficacy of the current... 
Gastroenterology and Hepatology | HCV | Phase-1 Study | Protease Inhibitor | TMC435 | PLUS RIBAVIRIN | INTERFERON-ALPHA-2B | VIRUS | TELAPREVIR | SAFETY | GENOTYPES 1 | INFECTED INDIVIDUALS | THERAPY | PEGINTERFERON ALPHA-2A | GASTROENTEROLOGY & HEPATOLOGY | Simeprevir | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Protease Inhibitors - pharmacokinetics | Humans | Middle Aged | Hepacivirus - genetics | DNA, Viral - analysis | Male | RNA, Viral - blood | Young Adult | Time Factors | Protease Inhibitors - administration & dosage | Protease Inhibitors - adverse effects | Adult | Female | Heterocyclic Compounds, 3-Ring - pharmacokinetics | Hepacivirus - drug effects | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Viral Nonstructural Proteins - genetics | Genotype | Treatment Outcome | Antiviral Agents - administration & dosage | Sulfonamides - pharmacokinetics | Hepatitis C - diagnosis | Hepacivirus - enzymology | Antiviral Agents - adverse effects | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Sulfonamides - adverse effects | Viral Load - drug effects | Viral Nonstructural Proteins - antagonists & inhibitors | Sulfonamides - administration & dosage | Medical colleges | Medical research | Protease inhibitors | Proteases | Interferon alpha | Medicine, Experimental | Biological response modifiers | Hepatitis C
Journal Article
BMC Gastroenterology, ISSN 1471-230X, 02/2017, Volume 17, Issue 1, p. 26
Background: A Phase 2a, open-label study (NCT01724086) was conducted to assess the efficacy and safety of a once-daily, 2-direct-acting-antiviral-agent (2-DAA)... 
Simeprevir | Direct-acting antiviral agents | Genotype 1 | Efficacy | TMC647055/ritonavir | Safety | Hepatitis C virus | JNJ-56914845 | Ribavirin | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | TMC647055 | PROTEASE INHIBITOR | DASABUVIR | C VIRUS-INFECTION | PHASE-3 TRIAL | DOUBLE-BLIND | genotype 1 | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | Antiviral Agents - pharmacokinetics | Humans | Middle Aged | Male | Carbamates - pharmacokinetics | Simeprevir - therapeutic use | Simeprevir - adverse effects | Simeprevir - pharmacokinetics | Ritonavir - adverse effects | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Ribavirin - pharmacokinetics | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Antiviral Agents - therapeutic use | Valine - pharmacokinetics | Ribavirin - therapeutic use | Valine - analogs & derivatives | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Hepatitis C, Chronic - drug therapy | Sulfonamides - pharmacokinetics | Ritonavir - pharmacokinetics | Heterocyclic Compounds, 4 or More Rings - pharmacokinetics | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Valine - therapeutic use | Aged | Valine - adverse effects | Carbamates - therapeutic use | Hepatitis C, Chronic - genetics
Journal Article
Antiviral therapy, 2011, Volume 16, Issue 7, p. 1021
Journal Article